Broker rates these 2 top ASX 200 shares as buys in July

Hub24 and ResMed are among this broker's favourites.

| More on:
Person pressing the buy button on a smartphone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Brokers are always on the hunt for opportunities. Ord Minnett has picked out two ASX 200 share ideas
  • ResMed is one of the leading ASX healthcare shares. It aims to help patients with sleep apnea
  • Hub24 is one of Australia’s leading fintech companies

The S&P/ASX 200 Index (ASX: XJO) could be the place to look for shares that are leaders in their industry, while also being good value.

But which ASX shares should investors go for? The broker Ord Minnett has named some companies it thinks are opportunities to buy.

Recent volatility makes it tricky to know which shares are the best value. However, brokers like to name share price targets, which is their best guess about where a share price will be in 12 months.

While a share price target is certainly not a guarantee of returns, it can indicate how much potential an ASX share may have in the broker's eyes.

These two are rated as buys by Ord Minnett and seemingly have good upside potential.

ResMed Inc (ASX: RMD)

ResMed is an expert in helping people with sleep apnea. The company says it has innovative solutions that treat and keep people out of hospital, empowering them to live healthier, higher-quality lives.

It says it has digital health technologies and cloud-connected medical devices that can transform care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases. It operates in more than 140 countries.

Ord Minnett recently focused on the news that the ASX 200 share will acquire Medifox Dan for approximately US$1 billion. This company specialises in software solutions for professional and non-professional care, therapeutic practices and child, family and youth welfare facilities. It also has digital solutions for modern training and education management.

Medifox Dan made pro forma net revenue of US$83 million in 2021, with pro forma adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of approximately $35 million.

While Ord Minnett rates ResMed as a buy with a price target of $35, it thought the acquisition price was high considering what's going on globally with the decline of share prices.

At the time of writing, the ResMed share price is up 0.8% at $31.05.

Hub24 Ltd (ASX: HUB)

Hub24 is a platform business in the financial technology (fintech) world. It has different segments including Hub24, Xplore, HUBconnect and Class.

The company boasts that it is Australia's fastest-growing platform provider. Hub24's market share has grown to around 5%, with an ongoing strong share of net flows.

It aims to lead the wealth industry as the best provider of an integrated platform, technology and data solutions.

The ASX 200 share is growing quickly. In the quarter for the three months to 31 March 2022, it saw net inflows of $2.6 billion, which was an increase of 36.4% year on year. Total funds under administration (FUA) was $68.3 billion at 31 March 2022 – platform FUA of $51 billion was up 43.3% year on year.

The financials are showing rapid growth. FY22 first-half platform segment revenue rose 76% to $77.3 million, while underlying net profit after tax (NPAT) went up 103% to $14.2 million.

It's currently rated as a buy by Ord Minnett, with a price target of $30. The broker thinks Hub24 has an attractive long-term future and can continue to achieve attractive inflows.

The Hub24 share price is up 0.59% to $20.41 in early trading on Thursday.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 Ltd and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended Hub24 Ltd and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Best Shares

A happy couple drinking red wine in a vineyard.
Best Shares

5 ASX 200 shares just upgraded to strong buy ratings

The experts say these 5 shares are set to rise over the next 12 months.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Best Shares

If I could only own 1 ASX stock, it would be this one

This stock offers investors a bit of everything.

Read more »

a girl stands in an apple orchard holding two red apples in raised arms with a happy, celebratory look on her face with a large smile and a pretty country background to the picture.
Best Shares

Top ASX shares to buy in March 2025

Looking to plant some new investment seeds right now?

Read more »

A woman walks along the street holding an oversized box wrapped as a gift.
Best Shares

Top ASX shares to buy following earnings surprises

Who doesn't love a surprise?

Read more »

Businessman smiles with arms outstretched after receiving good news.
Best Shares

Here are 3 of my most profitable investments in ASX shares ever (and which one I'd buy more of right now)

I reckon only one of these shares is worthy of a buy today.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Best Shares

Top oversold ASX shares to buy in February 2025

Hoping to bag an investment bargain this month?

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Best Shares

6 ASX 200 shares that could benefit from a weak Australia Dollar

This expert reckons a low dollar is unearthing opportunities.

Read more »

Two kids are selling big ideas from a lemonade stand on the side of the road for cheap!
Best Shares

Top ASX shares to buy in February 2025

Worried there are no great-value ASX shares left to buy? Our Foolish writers reckon these five are worth a good…

Read more »